PCM
TEVA icon

Pennant Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Pennant Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-50,000
Closed -$2.64M – 49
2014
Q1 		$2.64M Sell
50,000
-80,000
-62% -$3.7M 0.04% 45
2013
Q4 		$5.21M Buy
+130,000
New +$5.12M 0.09% 45

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Pennant Capital Management's TEVA Position: Q2 2014 in Review

Pennant Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2014, closing a stake of 50,000 shares — an estimated $2.64M sold.

Pennant Capital Management first reported a position in TEVA in Q4 2013 and held it in 2 quarters. The position peaked at $5.21M in Q4 2013. 779 funds tracked by Wall St. Rank hold TEVA as of Q2 2014.

  • Pennant Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Pennant Capital Management sold 50,000 Teva Pharmaceuticals shares in Q2 2014, an estimated $2.64M.
  • Pennant Capital Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Pennant Capital Management's Teva Pharmaceuticals position peaked at $5.21M in Q4 2013.
  • 779 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2014.

Based on Pennant Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.